Cargando…

Analysis of the cause of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy

OBJECTIVES: To investigate the causes of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy. METHODS: The clinical data of 759 patients who underwent transperineal prostate biopsy from March 2021 to June 2021 at Nanjing DrumTower Hospital were retrospectively analyzed. Twenty-one...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fan, Zhang, Shun, Huang, Haifeng, Zhang, Qing, Zhang, Shengjie, Zhang, Shiwei, Guo, Hongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074335/
https://www.ncbi.nlm.nih.gov/pubmed/35513861
http://dx.doi.org/10.1186/s12894-022-01021-8
_version_ 1784701461253324800
author Zhang, Fan
Zhang, Shun
Huang, Haifeng
Zhang, Qing
Zhang, Shengjie
Zhang, Shiwei
Guo, Hongqian
author_facet Zhang, Fan
Zhang, Shun
Huang, Haifeng
Zhang, Qing
Zhang, Shengjie
Zhang, Shiwei
Guo, Hongqian
author_sort Zhang, Fan
collection PubMed
description OBJECTIVES: To investigate the causes of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy. METHODS: The clinical data of 759 patients who underwent transperineal prostate biopsy from March 2021 to June 2021 at Nanjing DrumTower Hospital were retrospectively analyzed. Twenty-one patients had MRI contraindications. Ultimately, 738 patients completed mpMRI/TRUS fusion-guided targeted prostate biopsy + 12-core transperineal systematic biopsy after mpMRI and PI-RADS scoring. The pathological diagnoses from targeted and systematic biopsy were compared to evaluate and analyze the reasons for missed diagnoses in targeted biopsy. RESULTS: A total of 388 prostate cancer patients were identified, including 37 (9%) missed diagnoses with targeted biopsy and 44 (11.34%) with systematic biopsy. Between the target biopsy missed diagnosis group and not missed diagnosis group, there was no significant difference in age (71.08 ± 7.11 vs. 71.80 ± 7.94), but PSA (13.63 ± 12.41 vs. 54.54 ± 177.25 ng/ml), prostate volume (61.82 ± 40.64 vs. 44.34 ± 25.07 cm(3)), PSAD (0.27 ± 0.28 vs. 1.07 ± 2.91), and ISUP grade [1(1) vs. 3(2)] were significantly different. The pathological results of the 37 targeted biopsy missed diagnoses were recompared with MRI: 21 prostate cancers were normal on MRI; 9 cancer areas were abnormal on MRI; and 7 cancer areas on MRI were PI-RADS 3. CONCLUSIONS: Early prostate cancer, large prostate, effect of local anesthesia, doctor–patient cooperation, MRI diagnosis, and operator technology were possible factors for missed diagnosis in targeted biopsy. Improvements imaging technology, greater experience, and personalized biopsy may lead to an accurate pathological diagnosis.
format Online
Article
Text
id pubmed-9074335
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90743352022-05-07 Analysis of the cause of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy Zhang, Fan Zhang, Shun Huang, Haifeng Zhang, Qing Zhang, Shengjie Zhang, Shiwei Guo, Hongqian BMC Urol Research OBJECTIVES: To investigate the causes of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy. METHODS: The clinical data of 759 patients who underwent transperineal prostate biopsy from March 2021 to June 2021 at Nanjing DrumTower Hospital were retrospectively analyzed. Twenty-one patients had MRI contraindications. Ultimately, 738 patients completed mpMRI/TRUS fusion-guided targeted prostate biopsy + 12-core transperineal systematic biopsy after mpMRI and PI-RADS scoring. The pathological diagnoses from targeted and systematic biopsy were compared to evaluate and analyze the reasons for missed diagnoses in targeted biopsy. RESULTS: A total of 388 prostate cancer patients were identified, including 37 (9%) missed diagnoses with targeted biopsy and 44 (11.34%) with systematic biopsy. Between the target biopsy missed diagnosis group and not missed diagnosis group, there was no significant difference in age (71.08 ± 7.11 vs. 71.80 ± 7.94), but PSA (13.63 ± 12.41 vs. 54.54 ± 177.25 ng/ml), prostate volume (61.82 ± 40.64 vs. 44.34 ± 25.07 cm(3)), PSAD (0.27 ± 0.28 vs. 1.07 ± 2.91), and ISUP grade [1(1) vs. 3(2)] were significantly different. The pathological results of the 37 targeted biopsy missed diagnoses were recompared with MRI: 21 prostate cancers were normal on MRI; 9 cancer areas were abnormal on MRI; and 7 cancer areas on MRI were PI-RADS 3. CONCLUSIONS: Early prostate cancer, large prostate, effect of local anesthesia, doctor–patient cooperation, MRI diagnosis, and operator technology were possible factors for missed diagnosis in targeted biopsy. Improvements imaging technology, greater experience, and personalized biopsy may lead to an accurate pathological diagnosis. BioMed Central 2022-05-06 /pmc/articles/PMC9074335/ /pubmed/35513861 http://dx.doi.org/10.1186/s12894-022-01021-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhang, Fan
Zhang, Shun
Huang, Haifeng
Zhang, Qing
Zhang, Shengjie
Zhang, Shiwei
Guo, Hongqian
Analysis of the cause of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy
title Analysis of the cause of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy
title_full Analysis of the cause of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy
title_fullStr Analysis of the cause of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy
title_full_unstemmed Analysis of the cause of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy
title_short Analysis of the cause of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy
title_sort analysis of the cause of missed diagnosis in mpmri/trus fusion-guided targeted prostate biopsy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074335/
https://www.ncbi.nlm.nih.gov/pubmed/35513861
http://dx.doi.org/10.1186/s12894-022-01021-8
work_keys_str_mv AT zhangfan analysisofthecauseofmisseddiagnosisinmpmritrusfusionguidedtargetedprostatebiopsy
AT zhangshun analysisofthecauseofmisseddiagnosisinmpmritrusfusionguidedtargetedprostatebiopsy
AT huanghaifeng analysisofthecauseofmisseddiagnosisinmpmritrusfusionguidedtargetedprostatebiopsy
AT zhangqing analysisofthecauseofmisseddiagnosisinmpmritrusfusionguidedtargetedprostatebiopsy
AT zhangshengjie analysisofthecauseofmisseddiagnosisinmpmritrusfusionguidedtargetedprostatebiopsy
AT zhangshiwei analysisofthecauseofmisseddiagnosisinmpmritrusfusionguidedtargetedprostatebiopsy
AT guohongqian analysisofthecauseofmisseddiagnosisinmpmritrusfusionguidedtargetedprostatebiopsy